Biocon partners with Tabuk Pharmaceuticals as it expands in the Middle East
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Launching in 2022, its availability will be expanded to the global market
Subscribe To Our Newsletter & Stay Updated